Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I believe are of special interest to us survivors of advanced prostate cancer.
Today’s review includes two abstracts about Provenge (Sipuleucel-T).
Because of the number of recently approved new treatments for advanced prostate cancer we are now wrestling with the issue how to sequence (in what order should the drugs be taken) and which drugs should be combined (in the manner we currently use treatments for AIDES).
The first is Abstract (#34) speaks to the sequencing of two FDA approved treatments, specifically Provenge and hormone therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC or a PSA only recurrence). The data presented came from a Randomized Phase II Trial.
In the trial, Provenge